BRPI0408061A - tratamento médico utilizando um agonista de receptores seletivos de ep 2 - Google Patents

tratamento médico utilizando um agonista de receptores seletivos de ep 2

Info

Publication number
BRPI0408061A
BRPI0408061A BRPI0408061-0A BRPI0408061A BRPI0408061A BR PI0408061 A BRPI0408061 A BR PI0408061A BR PI0408061 A BRPI0408061 A BR PI0408061A BR PI0408061 A BRPI0408061 A BR PI0408061A
Authority
BR
Brazil
Prior art keywords
facilitating
receptor agonist
treating
repair
medical treatment
Prior art date
Application number
BRPI0408061-0A
Other languages
English (en)
Inventor
Alexander Angelo Constan
Prakash Raj Keshary
David Burton Maclean
Vishwas Madhav Paralkar
Doina Cosma Roman
David Duane Thompson
Timothy Michael Wright
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0408061A publication Critical patent/BRPI0408061A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"TRATAMENTO MéDICO UTILIZANDO UM AGONISTA DE RECEPTORES SELETIVOS DE EP~ 2~". A presente invenção refere-se a métodos de tratamento de hipertensão pulmonar, facilitação da fusão de articulações, facilitação da reparação de tendões e ligamentos, redução da ocorrência de fratura secundária, tratamento de necrose avascular, facilitação da reparação de cartilagem, facilitação da cicatrização óssea após o transplante de membros, facilitação da regeneração do fígado, facilitação da cicatrização de feridas, redução da ocorrência de ulceração gástrica, tratamento da hipertensão, facilitação do crescimento do esmalte dentário ou de unhas dos dedos das mãos ou dos pés, tratamento de glaucoma, tratamento da hipertensão ocular e reparação das lesões provocadas por doença óssea metastática utilizando um agonista de receptores seletivos de EP~ 2~.
BRPI0408061-0A 2003-03-04 2004-02-23 tratamento médico utilizando um agonista de receptores seletivos de ep 2 BRPI0408061A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45188903P 2003-03-04 2003-03-04
PCT/IB2004/000553 WO2004078169A1 (en) 2003-03-04 2004-02-23 Use of ep2 selective receptor agonists in medical treatment

Publications (1)

Publication Number Publication Date
BRPI0408061A true BRPI0408061A (pt) 2006-02-14

Family

ID=32962656

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408061-0A BRPI0408061A (pt) 2003-03-04 2004-02-23 tratamento médico utilizando um agonista de receptores seletivos de ep 2

Country Status (14)

Country Link
EP (1) EP1601351A1 (pt)
JP (1) JP2006519250A (pt)
KR (1) KR20050105511A (pt)
CN (1) CN1859903A (pt)
AU (1) AU2004216898A1 (pt)
BR (1) BRPI0408061A (pt)
CA (1) CA2518193A1 (pt)
CL (1) CL2004000412A1 (pt)
MX (1) MXPA05009398A (pt)
NZ (1) NZ541828A (pt)
PL (1) PL378748A1 (pt)
TW (1) TW200424176A (pt)
WO (1) WO2004078169A1 (pt)
ZA (1) ZA200506532B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005009468A1 (ja) * 2003-07-25 2005-02-03 Ono Pharmaceutical Co., Ltd. 軟骨関連疾患治療剤
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
MX2007007919A (es) 2004-12-31 2008-01-22 Reddy Us Therapeutics Inc Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
US7915316B2 (en) 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
US7696235B2 (en) * 2005-08-29 2010-04-13 Allergan, Inc. EP2 receptor agonists for treating glaucoma
EP1999255A2 (en) 2006-03-24 2008-12-10 The Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
AU2007280130B2 (en) 2006-07-28 2011-09-22 Pfizer Products Inc. EP2 agonists
EP3824885A1 (en) * 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
HUE025137T2 (en) * 2007-08-21 2016-01-28 Senomyx Inc Compositions are bitter taste blocking (blocking) compounds
HRP20190509T1 (hr) * 2008-03-12 2019-05-03 Ube Industries, Ltd. Spoj piridilaminooctene kiseline
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
PT2415763E (pt) 2009-03-30 2016-03-30 Ube Industries Composição farmacêutica para tratamento ou prevenção do glaucoma
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
CN102498101A (zh) * 2009-09-11 2012-06-13 宇部兴产株式会社 苯胺化合物
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 N-置換ヘテロアリール化合物
CA2773998A1 (en) * 2009-09-11 2011-03-17 Ube Industries, Ltd. Substituted carbonyl compound
WO2011030873A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 ベンジル化合物
WO2011030865A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 置換ベンジル化合物
WO2011030872A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 スルホンアミド化合物
KR20120101722A (ko) * 2009-12-25 2012-09-14 우베 고산 가부시키가이샤 아미노피리딘 화합물
JP5964965B2 (ja) 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質(cetp)インヒビターとしての置換複素環式アミン化合物
IN2014CN02290A (pt) 2011-09-27 2015-06-19 Reddys Lab Ltd Dr
CN104066837B (zh) 2011-12-02 2020-12-08 菲特治疗公司 增强的干细胞组合物
EP2785350B1 (en) 2011-12-02 2018-05-02 Fate Therapeutics, Inc. Improved methods of treating ischemia
EP2804605A4 (en) * 2012-01-20 2015-07-08 Acucela Inc SUBSTITUTED HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASES
CA2891595A1 (en) * 2012-11-16 2014-05-22 Allergan, Inc. Compounds and methods for skin repair
US10851412B2 (en) 2013-03-15 2020-12-01 Fate Therapeutics, Inc. Cell potency assay for therapeutic potential
BR112015024743A2 (pt) 2013-03-28 2017-07-18 Ube Industries composto de biarila substituída
HRP20241236T1 (hr) 2014-05-13 2024-12-06 Novartis Ag Spojevi i pripravci za induciranje hondrogeneze
CN106397149B (zh) * 2016-08-26 2019-05-21 大连奇凯医药科技有限公司 五氟苯甲醛的制备方法
CN115636761B (zh) * 2021-07-20 2024-07-05 中国石油天然气股份有限公司 一种油溶性表面活性剂、驱油剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2113787A1 (en) * 1993-01-29 1994-07-30 Nobuyuki Hamanaka Carbocyclic sulfonamides
DK0951282T3 (da) * 1996-12-20 2008-07-14 Pfizer Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US6376533B1 (en) * 2000-10-20 2002-04-23 Allergan Sales, Inc. Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists

Also Published As

Publication number Publication date
WO2004078169A8 (en) 2005-04-21
WO2004078169A1 (en) 2004-09-16
PL378748A1 (pl) 2006-05-15
EP1601351A1 (en) 2005-12-07
TW200424176A (en) 2004-11-16
CA2518193A1 (en) 2004-09-16
CN1859903A (zh) 2006-11-08
ZA200506532B (en) 2007-03-28
NZ541828A (en) 2008-06-30
AU2004216898A1 (en) 2004-09-16
JP2006519250A (ja) 2006-08-24
KR20050105511A (ko) 2005-11-04
CL2004000412A1 (es) 2005-02-04
MXPA05009398A (es) 2005-12-05

Similar Documents

Publication Publication Date Title
WO2004078169A8 (en) Use of ep2 selective receptor agonists in medical treatment
Crockarell et al. Early experience and results with the periacetabular osteotomy: the Mayo Clinic experience
PT881908E (pt) Utilizacao dos factores de crescimento de fibroblasto para estimular o crescimento osseo
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
BR0111237A (pt) Implante para um osso, aparelho osteosintético e processo para fixação de um úmero fraturado
EP0830138A4 (en) USE OF FIBROBLAST GROWTH FACTORS FOR STIMULATING BONE GROWTH
DE60120372D1 (de) Verwendung von insulin zur behandlung von knorpelkrankheiten
EP0950417A3 (en) Treatment of skeletal disorders
Atesalp et al. Treatment of tibial bone defects with the Ilizarov circular external fixator in high-velocity gunshot wounds
Bundgaard et al. Tibial bone loss and soft-tissue defect treated simultaneously with Ilizarov-technique--a case report
Walker Discussion: Open reduction of condylar fractures of the mandible in conjunction with repair of discal injury: A preliminary report
US20230218324A1 (en) Bone reductionand plate fixation forceps
Kaushal et al. Comminuted intra-articular fractures of the distal humerus
RU2285478C2 (ru) Способ лечения застарелого вывиха головки локтевой кости
RU2278629C2 (ru) Способ коррекции тяжелой сгибательной контрактуры коленного сустава
RU2000103308A (ru) Способ остеосинтеза внутрисуставных компрессионных переломов мыщелков большеберцовой кости под контролем артроскопии
RU2264185C1 (ru) Способ лечения привычного вывиха плеча
Laverick et al. Re: Devlin et al. Open reduction and internal fixation of fractured mandibular condyles by a retromandibular approach: surgical morbidity and informed consent. Br J Oral Maxillofac Surg 2002; 40: 23-25
ATE270863T1 (de) Gelenkimplantat und zugehörige hilfsinstrumente
RU2208409C2 (ru) Способ открытого вправления локтевой кости при ее застарелом вывихе
SU1367957A1 (ru) Способ лечени врожденного расщеплени кисти
RU2392895C1 (ru) Способ хирургического лечения привычного вывиха плеча
SU1503774A1 (ru) Способ лечени деформирующего артроза коленного сустава
RU2025097C1 (ru) Способ лечения сгибательной контрактуры коленного сустава
RU2000104552A (ru) Способ лечения передне-наружной ротационной нестабильности коленного сустава

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.